$2M Debt Funding for Stromedix
Summary
$2M Debt Funding for Stromedix Xconomy Boston — Stromedix, a Cambridge, MA-based developer of treatments for a cause of organ failure known as fibrosis, has raised $2 million of a prosposed $15.5 million round of debt financing, according to an SEC filing.The company, founded in 2007, has previously raised $29.4 million from investors including Atlas Venture, Bessemer Venture Partners, Red Abbey Venture Partners, New Leaf Venture Partners, and Frazier Healthcare Ventures.The company’s CEO, Michael Gilman, said in an e-mail that he was not able to be interviewed about the new financing today.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected